Cardiac safety of trabectedin monotherapy and in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.

Robin L. Jones,Thomas J. Herzog,Shreyaskumar Patel,Margaret von Mehren,Scott M. Schuetze,Brian A. Van Tine,Robert L. Coleman,Spyridon Triantos,Peter Hu,Waleed S.W. Shalaby,Tracy McGowan,Bradley J. Monk,George D. Demetri

Cardiac safety of trabectedin monotherapy and in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.

2020

Robin L. Jones
Thomas J. Herzog
Shreyaskumar Patel
Margaret von Mehren
Scott M. Schuetze
Brian A. Van Tine
Robert L. Coleman
Spyridon Triantos
Peter Hu
Waleed S.W. Shalaby
Tracy McGowan
Bradley J. Monk
George D. Demetri

11547Background: Trabectedin (T) is an established option as monotherapy for advanced soft tissue sarcomas (STS; Leiomyosarcomas and Liposarcomas in the USA) and in combination with pegylated lipos...

Keywords:

Oncology
Ovarian cancer
in patient
Trabectedin
Internal medicine
Pathology
Medicine
Pegylated Liposomal Doxorubicin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations